相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited
Uwe Fuhr et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59 (2019)
A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis
Yun Kim et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism
Josefine Schulz et al.
DRUG METABOLISM REVIEWS (2019)
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
A. J. Ullmann et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects
William L. Marshall et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
Nina Hanke et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects
Li Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole
Fang Qi et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics
Nicolas Hohmann et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content
Y. Shirasaka et al.
PHARMACOGENOMICS JOURNAL (2016)
Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole
Nicolas Hohmann et al.
CLINICAL PHARMACOKINETICS (2016)
Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis
Haiying Jin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Updated guidelines for the diagnosis and management of aspergillosis
Elizabeth Ann Misch et al.
JOURNAL OF THORACIC DISEASE (2016)
A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
Hyewon Chung et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children
Nicole R. Zane et al.
CLINICAL PHARMACOKINETICS (2014)
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
H. Ruth Ashbee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?
Aniwaa Owusu Obeng et al.
PHARMACOTHERAPY (2014)
A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole
Sebastian Frechen et al.
CLINICAL PHARMACOKINETICS (2013)
Steady-state pharmacokinetics and metabolism of voriconazole in patients
Marcus J. P. Geist et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Pharmacokinetics and Short-Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIV-Negative Volunteers
Thomas N. Kakuda et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring
Yukihiro Hamada et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2013)
Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults
Lena E. Friberg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory
Charles M. Strom et al.
GENETICS IN MEDICINE (2012)
Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers
SeungHwan Lee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling
Michaela Meyer et al.
DRUG METABOLISM AND DISPOSITION (2012)
Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use
Bharat Damle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
The Original Michaelis Constant: Translation of the 1913 Michaelis-Menten Paper
Kenneth A. Johnson et al.
BIOCHEMISTRY (2011)
Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles
Hiroshi Yamazaki et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Lack of Effect of Ginkgo biloba on Voriconazole Pharmacokinetics in Chinese Volunteers Identified as CYP2C19 Poor and Extensive Metabolizers
He-Ping Lei et al.
ANNALS OF PHARMACOTHERAPY (2009)
Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A
Seongwook Jeong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
Ina Scholz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
Guo Wang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
Johanna Weiss et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers
Bharat Damle et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects
Emma Andrews et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2008)
Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes
Souzan B. Yanni et al.
DRUG METABOLISM AND DISPOSITION (2008)
Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects
Ping Liu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects
Ping Liu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes
Norie Murayama et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults
J. Keirns et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets
E. S. Dodds Ashley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life
Teijo I. Saari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Potent cytochrome P4502C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
Gerd Mikus et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
TI Saari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacokinetic/pharmacodynamic profile of voriconazole
Ursula Theuretzbacher et al.
CLINICAL PHARMACOKINETICS (2006)
Development and evaluation of a generic physiologically based pharmacokinetic model for children
Andrea N. Edginton et al.
CLINICAL PHARMACOKINETICS (2006)
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin
JA Dowell et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics
J Rengelshausen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Voriconazole - a new therapeutic agent with an extended spectrum of antifungal activity
JP Donnelly et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human
SJ Roffey et al.
DRUG METABOLISM AND DISPOSITION (2003)
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
R Hyland et al.
DRUG METABOLISM AND DISPOSITION (2003)
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole
N Wood et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Effect of food on the pharmacokinetics of multiple-dose oral voriconazole
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Histamine H-2-receptor antagonists have no clinicafly significant effect on the steady-state pharmacokinetics of voriconazole
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
R Herbrecht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens
L Purkins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
分享论文
